Dong Chen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1258212/publications.pdf

Version: 2024-02-01

		516710	477307
72	974	16	29
papers	citations	h-index	g-index
73	73	73	1943
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients. Blood Cancer Journal, 2022, 12, 12.	6.2	1
2	Evaluation of soluble fibrin monomer complex in patients in SARSâ€CoVâ€2 COVIDâ€19 infectionâ€associated coagulopathy. European Journal of Haematology, 2022, 108, 319-326.	2.2	5
3	Mast cell sarcoma: clinicopathologic and molecular analysis of 10 new cases and review of literature. Modern Pathology, 2022, 35, 865-874.	5.5	7
4	DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation. Frontiers in Oncology, 2022, 12, 849376.	2.8	9
5	A dynamic 3â€factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy. American Journal of Hematology, 2022, 97, 1127-1134.	4.1	7
6	Platelet transfusion: The effects of a fluid warmer on platelet function. Transfusion, 2021, 61, 52-56.	1.6	3
7	Coreâ€binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. International Journal of Laboratory Hematology, 2021, 43, e19-e25.	1.3	6
8	A prospective, blinded study of a PF4-dependent assay for HIT diagnosis. Blood, 2021, 137, 1082-1089.	1.4	28
9	Myelodysplastic syndrome with t(6;9)(p22;q34.1)/DEK-NUP214 better classified as acute myeloid leukemia? A multicenter study of 107 cases. Modern Pathology, 2021, 34, 1143-1152.	5.5	12
10	Mayo Clinic experience with 1123 adults with acute myeloid leukemia. Blood Cancer Journal, 2021, 11, 46.	6.2	6
11	Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring <i>SF3B1</i> Mutations. American Journal of Clinical Pathology, 2021, 156, 679-690.	0.7	10
12	The Interlaboratory Performance in Measurement of Dabigatran and Rivaroxaban: Results of the College of American Pathologists External Quality Assessment Program. Archives of Pathology and Laboratory Medicine, 2021, , .	2.5	1
13	A novel likely-pathogenic variant in a patient with Hermansky-Pudlak Syndrome. Journal of Physical Education and Sports Management, 2021, 7, mcs.a006110.	1.2	0
14	Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes. American Journal of Hematology, 2021, 96, 1450-1460.	4.1	19
15	Revisiting the effects of spectral interfering substances in optical endâ€point coagulation assays. International Journal of Laboratory Hematology, 2021, 43, 1181-1190.	1.3	4
16	No Diagnostic Utility of Zero Heparin Control Buffer in Serotonin Release Assay: Findings from a Validation Study. Blood, 2021, 138, 3227-3227.	1.4	0
17	Diagnostic Utility of High Dose Heparin Confirmation Step in Heparin Induced Thrombocytopenia ELISA Assay. Blood, 2021, 138, 3228-3228.	1.4	0
18	Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis. Modern Pathology, 2020, 33, 334-343.	5 . 5	18

#	Article	IF	CITATIONS
19	Evidence for the Misfolding of the A1 Domain within Multimeric von Willebrand Factor in Type 2 von Willebrand Disease. Journal of Molecular Biology, 2020, 432, 305-323.	4.2	8
20	Secondary acquisition of BCR-ABL1 fusion in de novo GATA2-MECOM positive acute myeloid leukemia with subsequent emergence of a rare KMT2A-ASXL2 fusion. Cancer Genetics, 2020, 241, 67-71.	0.4	3
21	An In Silico Exploration of the Factors That Affect the Precision of the Bethesda Assay. American Journal of Clinical Pathology, 2020, 154, 671-682.	0.7	0
22	Characteristics of late transplantâ€associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. American Journal of Hematology, 2020, 95, 1170-1179.	4.1	19
23	Aetiology and outcomes of secondary myelofibrosis occurring in the context of inherited platelet disorders: A single institutional study of four patients. British Journal of Haematology, 2020, 190, e316-e320.	2.5	9
24	Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia. Blood Cancer Journal, 2020, 10, 15.	6.2	101
25	The significance of genetic mutations and their prognostic impact on patients with incidental finding of isolated del(20q) in bone marrow without morphologic evidence of a myeloid neoplasm. Blood Cancer Journal, 2020, 10, 7.	6.2	14
26	Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms. Leukemia, 2020, 34, 2519-2524.	7.2	25
27	Evaluation of Soluble Fibrin Monomer Complex in Patients with Sars-Cov-2 COVID-19 Infection. Blood, 2020, 136, 27-28.	1.4	3
28	Detection of Monoclonal Immunoglobulin By Mass Spectrometry in Patients Evaluated for Thrombotic Microangiopathy (TMA). Blood, 2020, 136, 17-17.	1.4	0
29	Determination of Relapse Risk By Complement Gene Variants after Eculizumab Discontinuation in Complement-Mediated Thrombotic Microangiopathy: A Retrospective Review. Blood, 2020, 136, 25-26.	1.4	1
30	Thrombophilia Testing Practices: The Mayo Clinic Experience. Blood, 2020, 136, 39-40.	1.4	0
31	Spectrum of Hematological Malignancies in 130 Patients with Germline Predisposition Syndromes - Mayo Clinic Germline Predisposition Study. Blood, 2020, 136, 34-35.	1.4	0
32	External Quality Assurance of Platelet Function Assays: Results of the College of American Pathologists Proficiency Testing Program. Archives of Pathology and Laboratory Medicine, 2019, 143, 472-482.	2.5	11
33	Lysosomal Storage and Albinism Due to Effects of a De Novo CLCN7 Variant on Lysosomal Acidification. American Journal of Human Genetics, 2019, 104, 1127-1138.	6.2	59
34	Effects of a fully magnetically levitated centrifugal-flow or axial-flow left ventricular assist device on von Willebrand factor: A prospective multicenter clinical trial. Journal of Heart and Lung Transplantation, 2019, 38, 806-816.	0.6	61
35	Hermansky-Pudlak syndrome and oculocutaneous albinism in Chinese children with pigmentation defects and easy bruising. Orphanet Journal of Rare Diseases, 2019, 14, 52.	2.7	13
36	Heat inactivation of extended halfâ€life factor VIII concentrates. Haemophilia, 2019, 25, e130-e131.	2.1	5

#	Article	IF	CITATIONS
37	Factor V Deficiency with a Thrombotic Clinical Phenotype. Seminars in Thrombosis and Hemostasis, 2019, 45, 108-112.	2.7	5
38	Characteristics and Outcomes of Therapy Related Myeloid Neoplasms in Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation. Blood, 2019, 134, 4560-4560.	1.4	1
39	Spectrum of Abnormalities and Clonal Transformation in Germline RUNX1 Familial Platelet Disorder and a Comparative Analysis with Somatic RUNX1 Mutations in Myeloid Neoplasms. Blood, 2019, 134, 3003-3003.	1.4	1
40	Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be Beneficial. Blood, 2019, 134, 3863-3863.	1.4	1
41	Greatly increased giant platelets mimicking blasts in flow cytometric analysis from a patient with primary myelofibrosis. Journal of Hematopathology, 2018, 11, 21-22.	0.4	O
42	STAT3 mutation and its clinical and histopathologic correlation in T-cell large granular lymphocytic leukemia. Human Pathology, 2018, 73, 74-81.	2.0	49
43	Clinical spectrum and clonal evolution in germline syndromes with predisposition to myeloid neoplasms. British Journal of Haematology, 2018, 182, 141-145.	2.5	4
44	Factor IX Gene (F9) Genotyping Trends and Spectrum of Mutations Identified: A Reference Laboratory Experience. Seminars in Thrombosis and Hemostasis, 2018, 44, 287-292.	2.7	2
45	A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and <i>FLT3â€ITD</i> mutational status. American Journal of Hematology, 2018, 93, E401-E404.	4.1	3
46	Clinical and laboratory diagnosis of autoimmune factor V inhibitors: A single institutional experience. Thrombosis Research, 2018, 171, 14-21.	1.7	7
47	Coreâ€binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (l―CBF) Tj	ETQq] 1 ().784314 rgB
48	Identification of a Novel Heterozygous Mutation (c.2213T>G;p.Leu738Arg) in Platelet Glycoprotein ITGB3 gene in a Patient with Glanzmann's Thrombasthenia. Blood, 2018, 132, 1158-1158.	1.4	0
49	Novel Hermanksky-Pudlak Syndrome Type 6 Missense Variant Associated with Subclinical Oculocutaneous Albinism and Mild Bleeding. Blood, 2018, 132, 1153-1153.	1.4	O
50	1,123 Consecutive Adults with Non-APL Acute Myeloid Leukemia: The Mayo Clinic Experience. Blood, 2018, 132, 2689-2689.	1.4	0
51	Combined alpha-delta platelet storage pool deficiency is associated with mutations in GFI1B. Molecular Genetics and Metabolism, 2017, 120, 288-294.	1.1	22
52	Clinical characteristics and platelet phenotype in a family with <i>RUNX1 </i> mutated thrombocytopenia. Leukemia and Lymphoma, 2017, 58, 1963-1967.	1.3	10
53	Grey platelet syndrome misdiagnosed as <scp>ITP</scp> . British Journal of Haematology, 2016, 173, 662-662.	2.5	5
54	Nextâ€generation sequencing in systemic mastocytosis: Derivation of a mutationâ€augmented clinical prognostic model for survival. American Journal of Hematology, 2016, 91, 888-893.	4.1	60

#	Article	IF	CITATIONS
55	BCR–JAK2 fusion in a myeloproliferative neoplasm with associated eosinophilia. Cancer Genetics, 2016, 209, 223-228.	0.4	19
56	Thrombotic Microangiopathy Care Pathway: A Consensus Statement for the Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy (CAP-TMA) Disease-Oriented Group. Mayo Clinic Proceedings, 2016, 91, 1189-1211.	3.0	55
57	Testing for dabigatran and rivaroxaban by clinical laboratories. American Journal of Hematology, 2016, 91, E464-E467.	4.1	7
58	Usefulness of Von Willebrand Factor Activity Indexes toÂPredict Therapeutic Response in Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2016, 117, 436-442.	1.6	16
59	Hepatosplenic T-cell lymphoma with blastoid morphology in a patient with Crohn disease. Blood, 2016, 128, 2275-2275.	1.4	2
60	GFI1B Mutation Associated Alpha-Delta Platelet Storage-Pool Deficiency: A Case Report and Its Potential Important Implication. Blood, 2016, 128, 3727-3727.	1.4	0
61	Not all <i>CALR</i> mutations are created equal. Leukemia and Lymphoma, 2015, 56, 2482-2483.	1.3	6
62	York platelet syndrome is a CRAC channelopathy due to gain-of-function mutations in STIM1. Molecular Genetics and Metabolism, 2015, 114, 474-482.	1.1	94
63	Novel Genetic Variants in Complement-Mediated Thrombotic Microangiopath. Blood, 2015, 126, 1050-1050.	1.4	3
64	Patients with Therapy-Related Myelodysplastic Syndromes (t-MDS) Have Shorter Median Overall Survival Than De Novo MDS: Mayo Clinic Experience. Blood, 2015, 126, 5234-5234.	1.4	3
65	Local Verification and Assignment of Mean Normal Prothrombin Time and International Sensitivity Index Values across Various Instruments: Recent Experience and Outcome from North America. Seminars in Thrombosis and Hemostasis, 2014, 40, 115-120.	2.7	20
66	From Vitamin K Antagonists to Liver International Normalized Ratio: A Historical Journey and Critical Perspective. Seminars in Thrombosis and Hemostasis, 2014, 40, 845-851.	2.7	13
67	Indexes of von Willebrand Factor as Biomarkers of Aortic Stenosis Severity (from the Biomarkers of) Tj ETQq $1\ 1$	0.784314 1.6	rgBT /Overlo
68	A Case of Hairy Cell Leukemia With CCND1-IGH@ Translocation. American Journal of Surgical Pathology, 2011, 35, 1080-1084.	3.7	9
69	Clinicopathologic Features of CDK6 Translocation-associated B-cell Lymphoproliferative Disorders. American Journal of Surgical Pathology, 2009, 33, 720-729.	3.7	24
70	Isolated Trisomy 8 in the Myelodysplastic Syndromes Blood, 2009, 114, 2785-2785.	1.4	0
71	Indolent Mantle Cell Lymphoma: A Distinct Subgroup Characterized by Leukemic Phase Disease without Lymphadenopathy Blood, 2009, 114, 3937-3937.	1.4	3
72	Charaterization of Human Primitive Megakaryocytes and "Plateletsâ€. Blood, 2006, 108, 1520-1520.	1.4	0